Tirzepatide is a new type of GIP/GLP-1 receptor double agonist withpotent glucose control and weight loss effects. It was approved by the USFDA in May 2022 as an adjoint therapy with diet and exercise to improveblood glucose control in adults with type 2 diabetes.
Product Characteristics
|
Item |
Specification |
Result |
|
Appearance |
White or almost white powder |
White powder |
|
Molecular Ion Mass |
4813.45 |
Conforms |
|
Purity (HPLC) |
≥99.0% |
Conforms |
|
Peptide Content (HPLC) |
≥90.0% |
Conforms |
|
Sodium Ion (C) |
≤ 5.0% |
Conforms |
|
Water Content (K.F) |
≤ 8.0% |
Conforms |
|
pH |
7.0～9.0 (C=5mg/ml) |
Conforms |
|
Solubility |
Report Value |
50mg/ml (H₂O) |
|
Endotoxin |
≤ 10 EU/mg |
Conforms |
|
Microbial Limits |
TAMC≤50 cfu/0.1g; TYMC≤50 cfu/0.1g |
Conforms |
|
Storage |
/ |
Store in a sealed container, protect from light, and store at -20±5°C. |
Product Advantages
- Production Form: Fully synthetic, significant weight loss, good GLP-1 agonist activity, and GIP receptor agonist activity.
- Production Advantages: Double agonist, high purity, high yield, and affordable price.
Our product is intended for research use only and is not for individual consumer use.
For more information and product catalogs, please email: info@uniwellbio.com or call: +86 28 88808601 or leave a message online. We are happy to serve you.
Health Care Product, Dietary Supplements, Cosmetics
